Lung CancerNCT07441863
Structured Pulmonary Physiotherapy After Lung Cancer Surgery by Age Group
An observational study of Lung Cancer and Postoperative Pulmonary Complications, run by Bezmialem Vakif University at 1 site in Turkey (Türkiye).
Trial summary
This ambispective observational cohort study aims to evaluate age-related differences in clinical outcomes among patients undergoing lung cancer surgery who received a structured comprehensive in-patient physiotherapy (CIPT) program as part of standard postoperative care. Read more about this study
- Who is it for?
- Ages 45 to 90 years
- Conditions the study is for
- Lung Cancer, Postoperative Pulmonary Complications
- What is being tested?
- Comprehensive In-Patient Physiotherapy (CIPT) Program
- Type of treatment
- Lifestyle or therapy programme
- How many people
- 60 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 1 Jun 2025to 2 Mar 2026
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 45 to 90 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Adults aged 45-90 years who underwent lung cancer surgery at Bezmialem Vakif University Hospital and received routine comprehensive in-patient physiotherapy (CIPT) as part of standard postoperative care. Eligible participants were hemodynamically stable during the early postoperative period and were classified into middle-aged (45-64 years) and older (65-90 years) cohorts for comparative analysis.
Who may be able to join
- Patients aged 45 to 90 years
- Undergoing lung cancer surgery (lobectomy, segmentectomy, or pneumonectomy)
- Medically stable in the early postoperative period
- Able to participate in a structured pulmonary physiotherapy program
- Provided written informed consent
Who cannot join
- Hemodynamic instability preventing mobilization
- Severe cognitive impairment limiting cooperation
- Neurological or orthopedic conditions restricting mobilization
- Requirement for prolonged mechanical ventilation
- Presence of another active malignancy
- Any medical contraindication to physiotherapy as determined by the attending physician
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Age-Related Effects of a Structured Postoperative Pulmonary Physiotherapy Program After Lung Cancer Surgery: An Ambispective Observational Cohort Study in Middle-aged and Older Patients
This ambispective observational cohort study aims to evaluate age-related differences in clinical outcomes among patients undergoing lung cancer surgery who received a structured comprehensive in-patient physiotherapy (CIPT) program as part of standard postoperative care. The CIPT program includes patient education, chest physiotherapy, breathing exercises, airway clearance techniques, early mobilization, postural exercises, and upper- and lower-extremity range-of-motion exercises during the postoperative hospital stay.
The primary outcome is hospital length of stay. Secondary outcomes include clinical parameters (blood pressure, resting heart rate, oxygen saturation, and respiratory rate), symptom-related outcomes (dyspnea, fatigue, and incisional pain), and inflammatory biomarkers (C-reactive protein, neutrophil-to-lymphocyte ratio, and albumin). Outcomes are analyzed according to predefined age groups (45-64 years and 65-90 years) to evaluate potential age-related differences.
Read the detailed description
This ambispective observational cohort study evaluates age-related differences in clinical outcomes among patients undergoing lung cancer surgery who received a structured comprehensive in-patient physiotherapy (CIPT) program as part of standard postoperative care. Patients aged 45-90 years were included and classified into two predefined age groups: middle-aged (45-64 years) and older (65-90 years).
The CIPT program was initiated on the first day after transfer from the intensive care unit to the thoracic surgery ward and continued until hospital discharge. The program included patient education, breathing exercises, incentive spirometry, airway clearance techniques, early mobilization, postural exercises, and upper- and lower-extremity range-of-motion exercises. One session per day was supervised by a physiotherapist, with additional sessions performed independently by the patient or with caregiver assistance during hospitalization.
The primary outcome was hospital length of stay. Secondary outcomes included clinical parameters (blood pressure, resting heart rate, oxygen saturation, and respiratory rate), symptom-related outcomes (dyspnea, fatigue, and incisional pain), and inflammatory biomarkers (C-reactive protein [CRP], neutrophil-to-lymphocyte ratio [NLR], and albumin).
Outcomes were assessed during the postoperative inpatient period and compared between the predefined age groups. No randomization or non-intervention control group was included, as all participants received the same structured CIPT program as part of standard postoperative care.
- Conditions
- Lung Cancer, Postoperative Pulmonary Complications
- Being tested
- Comprehensive In-Patient Physiotherapy (CIPT) Program
- Keywords
- pulmonary physiotherapy, pulmonary rehabilitation, lung cancer, early rehabilitation, thoracic surgery, lung cancer surgery, age-related outcomes
- Medical subject headings
- Lung Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Comprehensive In-Patient Physiotherapy (CIPT) ProgramBehavioural
The comprehensive in-patient physiotherapy (CIPT) program was provided as part of standard postoperative care following lung cancer surgery. The program included patient education, breathing exercises, incentive spirometry, airway clearance techniques, early mobilization, postural exercises, and upper- and lower-extremity range-of-motion exercises. It was initiated on the first day after transfer to the thoracic surgery ward and continued until hospital discharge. One session per day was supervised by a physiotherapist, with two additional sessions performed independently by the patient or with caregiver assistance
| Study group | Role | What they receive |
|---|---|---|
| Middle-aged group (45-64 years) | Participants aged 45-64 years who underwent lung cancer surgery and received the comprehensive in-patient physiotherapy (CIPT) program as part of standard postoperative care during hospitalization. Outcomes were assessed during the postoperative inpatient period and compared with those of the older cohort. Receives: Behavioral: Comprehensive In-Patient Physiotherapy (CIPT) Program | |
| Older group (65-90 years) | Participants aged 65-90 years who underwent lung cancer surgery and received the comprehensive in-patient physiotherapy (CIPT) program as part of standard postoperative care during hospitalization. Outcomes were assessed during the postoperative inpatient period and compared with those of the middle-aged cohort. Receives: Behavioral: Comprehensive In-Patient Physiotherapy (CIPT) Program |
What is being measured
The primary outcome is the main question the study is designed to answer.
Length of Hospital Stay
Length of hospital stay is defined as the number of days from postoperative admission to the ward until hospital discharge following lung cancer surgery.
Measured: Postoperative period, from ward admission after surgery until hospital discharge (maximum 30 postoperative days)
C-reactive protein (CRP)
Serum CRP levels (mg/L) will be measured to evaluate postoperative systemic inflammatory response.
Measured: Postoperative Day 1 and at hospital discharge (up to 30 days after surgery)
Peripheral Oxygen Saturation (SpO₂)
Peripheral oxygen saturation (%) will be measured using pulse oximetry to assess postoperative oxygenation status.
Measured: Postoperative Day 1 and at hospital discharge (up to 30 days after surgery)
Secondary outcomes (8)
Neutrophil-to-Lymphocyte Ratio (NLR)
NLR will be calculated from complete blood count parameters to assess systemic inflammatory status.
Measured: Postoperative Day 1 and at hospital discharge (up to 30 days after surgery)
Serum Albumin
Serum albumin levels (g/dL) will be measured to assess nutritional status.
Measured: Postoperative Day 1 and at hospital discharge (up to 30 days after surgery)
Systolic Blood Pressure
Systolic blood pressure (mmHg) will be recorded to assess postoperative hemodynamic response.
Measured: Postoperative Day 1 and at hospital discharge (up to 30 days after surgery)
Diastolic Blood Pressure
Diastolic blood pressure (mmHg) will be recorded to assess postoperative hemodynamic response.
Measured: Postoperative Day 1 and at hospital discharge (up to 30 days after surgery)
Heart Rate
Heart rate (beats per minute) will be measured to evaluate cardiovascular response during the postoperative period.
Measured: Postoperative Day 1 and at hospital discharge (up to 30 days after surgery)
Dyspnea Severity
Dyspnea severity will be assessed using the Modified Borg Dyspnea Scale (0-10), where 0 indicates "no breathlessness" and 10 indicates "maximal breathlessness."
Measured: Postoperative Day 1 and at hospital discharge (up to 30 days after surgery)
Fatigue Severity
Fatigue will be assessed using the Borg Rating of Perceived Exertion (0-10), where higher scores indicate greater perceived fatigue.
Measured: Postoperative Day 1 and at hospital discharge (up to 30 days after surgery)
Incisional Pain Intensity
Incisional pain will be evaluated using the Numeric Rating Scale (NRS, 0-10), where 0 represents "no pain" and 10 represents "worst imaginable pain."
Measured: Postoperative Day 1 and at hospital discharge (up to 30 days after surgery)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Mar 2026
- Study start1 Jun 2025
- Primary completion2 Mar 2026
- Study completion2 Mar 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Lung CancerStudies of the same condition, open and under way.
- More trials run by Bezmialem Vakif UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Other
- Enrolment
- 60 participants (actual)
Sponsor and investigators
- Lead sponsor
- Bezmialem Vakif University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Ayşe Sena Manzak, Bezmialem Vakif University
- Investigators
- Ayşe Sena Manzak Dursun, Assistant Professor, Principal investigator, Bezmialem Vakif University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07441863
- Sponsor's protocol ID
- 2026/72
- Status last verified
- Aug 2026
- First submitted
- 17 Feb 2026
- Last updated
- 17 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 17 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Age-Related Effects of a Structured Postoperative Pulmonary Physiotherapy Program After Lung Cancer Surgery: An Ambispective Observational Cohort Study in Middle-aged and Older Patients
- ClinicalTrials.gov ID
- NCT07441863
- Acronym / sponsor ID
- 2026/72
- Conditions
- Lung Cancer, Postoperative Pulmonary Complications
- Keywords
- pulmonary physiotherapy, pulmonary rehabilitation, lung cancer, early rehabilitation, thoracic surgery, lung cancer surgery, age-related outcomes
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 60 participants (actual)
- Lead sponsor
- Bezmialem Vakif UniversityUniversity, hospital or other
- Study start
- 1 Jun 2025 (actual)
- Primary completion
- 2 Mar 2026 (actual)
- Study completion
- 2 Mar 2026 (actual)
- First posted
- 2 Mar 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This ambispective observational cohort study aims to evaluate age-related differences in clinical outcomes among patients undergoing lung cancer surgery who received a structured comprehensive in-patient physiotherapy (CIPT) program as part of standard postoperative care. The CIPT program includes patient education, chest physiotherapy, breathing exercises, airway clearance techniques, early mobilization, postural exercises, and upper- and lower-extremity range-of-motion exercises during the postoperative hospital stay.
The primary outcome is hospital length of stay. Secondary outcomes include clinical parameters (blood pressure, resting heart rate, oxygen saturation, and respiratory rate), symptom-related outcomes (dyspnea, fatigue, and incisional pain), and inflammatory biomarkers (C-reactive protein, neutrophil-to-lymphocyte ratio, and albumin). Outcomes are analyzed according to predefined age groups (45-64 years and 65-90 years) to evaluate potential age-related differences.
Detailed description
This ambispective observational cohort study evaluates age-related differences in clinical outcomes among patients undergoing lung cancer surgery who received a structured comprehensive in-patient physiotherapy (CIPT) program as part of standard postoperative care. Patients aged 45-90 years were included and classified into two predefined age groups: middle-aged (45-64 years) and older (65-90 years).
The CIPT program was initiated on the first day after transfer from the intensive care unit to the thoracic surgery ward and continued until hospital discharge. The program included patient education, breathing exercises, incentive spirometry, airway clearance techniques, early mobilization, postural exercises, and upper- and lower-extremity range-of-motion exercises. One session per day was supervised by a physiotherapist, with additional sessions performed independently by the patient or with caregiver assistance during hospitalization.
The primary outcome was hospital length of stay. Secondary outcomes included clinical parameters (blood pressure, resting heart rate, oxygen saturation, and respiratory rate), symptom-related outcomes (dyspnea, fatigue, and incisional pain), and inflammatory biomarkers (C-reactive protein [CRP], neutrophil-to-lymphocyte ratio [NLR], and albumin).
Outcomes were assessed during the postoperative inpatient period and compared between the predefined age groups. No randomization or non-intervention control group was included, as all participants received the same structured CIPT program as part of standard postoperative care.
Study design
- Observational model
- Cohort
- Time perspective
- Other
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Middle-aged group (45-64 years) | – | Behavioral: Comprehensive In-Patient Physiotherapy (CIPT) ProgramParticipants aged 45-64 years who underwent lung cancer surgery and received the comprehensive in-patient physiotherapy (CIPT) program as part of standard postoperative care during hospitalization. Outcomes were assessed during the postoperative inpatient period and compared with those of the older cohort. |
| Older group (65-90 years) | – | Behavioral: Comprehensive In-Patient Physiotherapy (CIPT) ProgramParticipants aged 65-90 years who underwent lung cancer surgery and received the comprehensive in-patient physiotherapy (CIPT) program as part of standard postoperative care during hospitalization. Outcomes were assessed during the postoperative inpatient period and compared with those of the middle-aged cohort. |
Who may qualify
- Ages
- 45 to 90 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Adults aged 45-90 years who underwent lung cancer surgery at Bezmialem Vakif University Hospital and received routine comprehensive in-patient physiotherapy (CIPT) as part of standard postoperative care. Eligible participants were hemodynamically stable during the early postoperative period and were classified into middle-aged (45-64 years) and older (65-90 years) cohorts for comparative analysis.
Key inclusion criteria (5 listed)
- Patients aged 45 to 90 years
- Undergoing lung cancer surgery (lobectomy, segmentectomy, or pneumonectomy)
- Medically stable in the early postoperative period
- Able to participate in a structured pulmonary physiotherapy program
- Provided written informed consent
Key exclusion criteria (6 listed)
- Hemodynamic instability preventing mobilization
- Severe cognitive impairment limiting cooperation
- Neurological or orthopedic conditions restricting mobilization
- Requirement for prolonged mechanical ventilation
- Presence of another active malignancy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Comprehensive In-Patient Physiotherapy (CIPT) ProgramThe comprehensive in-patient physiotherapy (CIPT) program was provided as part of standard postoperative care following lung cancer surgery. The program included patient education, breathing exercises, incentive spirometry, airway clearance techniques, early mobilization, postural exercises, and upper- and lower-extremity range-of-motion exercises. It was initiated on the first day after transfer to the thoracic surgery ward and continued until hospital discharge. One session per day was supervised by a physiotherapist, with two additional sessions performed independently by the patient or with caregiver assistance | Behavioural | Middle-aged group (45-64 years), Older group (65-90 years) |
Primary outcome
Length of Hospital Stay
Time frame: Postoperative period, from ward admission after surgery until hospital discharge (maximum 30 postoperative days)
Length of hospital stay is defined as the number of days from postoperative admission to the ward until hospital discharge following lung cancer surgery.
C-reactive protein (CRP)
Time frame: Postoperative Day 1 and at hospital discharge (up to 30 days after surgery)
Serum CRP levels (mg/L) will be measured to evaluate postoperative systemic inflammatory response.
Peripheral Oxygen Saturation (SpO₂)
Time frame: Postoperative Day 1 and at hospital discharge (up to 30 days after surgery)
Peripheral oxygen saturation (%) will be measured using pulse oximetry to assess postoperative oxygenation status.
8 secondary outcomes
Neutrophil-to-Lymphocyte Ratio (NLR)
Time frame: Postoperative Day 1 and at hospital discharge (up to 30 days after surgery)
Serum Albumin
Time frame: Postoperative Day 1 and at hospital discharge (up to 30 days after surgery)
Systolic Blood Pressure
Time frame: Postoperative Day 1 and at hospital discharge (up to 30 days after surgery)
Diastolic Blood Pressure
Time frame: Postoperative Day 1 and at hospital discharge (up to 30 days after surgery)
Heart Rate
Time frame: Postoperative Day 1 and at hospital discharge (up to 30 days after surgery)
Dyspnea Severity
Time frame: Postoperative Day 1 and at hospital discharge (up to 30 days after surgery)
Fatigue Severity
Time frame: Postoperative Day 1 and at hospital discharge (up to 30 days after surgery)
Incisional Pain Intensity
Time frame: Postoperative Day 1 and at hospital discharge (up to 30 days after surgery)
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Aug 2026.
- Individual participant dataSharing planned: No
Related trials for Lung Cancer
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingObservational study
A Prospective ,Multicenter ,Non-interventional ,Real-world Study Observing Changes in Molecular Markers Osimertinib Targeted Therapy in EGFRm NSCLC
Non Small Cell Lung Cancer
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingPhase 3
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Non-Small Cell Lung Cancer (NSCLC)
Active, not recruitingPhase 2
Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer
Metastatic Lung Cancer, Advanced Non Small Cell Lung Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Ayşe Sena Manzak Dursun, Assistant Professor principal investigator
Bezmialem Vakif University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Lung Cancer and Postoperative Pulmonary Complications, run by Bezmialem Vakif University at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 17 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Length of Hospital Stay (time frame: Postoperative period, from ward admission after surgery until hospital discharge (maximum 30 postoperative days)). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Aug 2026.